Page last updated: 2024-08-23

etoposide and busulfan

etoposide has been researched along with busulfan in 203 studies

Research

Studies (203)

TimeframeStudies, this research(%)All Research%
pre-19908 (3.94)18.7374
1990's59 (29.06)18.2507
2000's59 (29.06)29.6817
2010's60 (29.56)24.3611
2020's17 (8.37)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Barbusca, E; Cannizzo, G; Cascioferro, S; Daidone, G; Maggio, B; Mancuso, S; Plescia, F; Raffa, D; Raimondi, MV; Tolomeo, M1
Lombardo, F; Obach, RS; Waters, NJ1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Ekins, S; Williams, AJ; Xu, JJ1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Copelan, EA1
Bocheńska, J; Glejzer, O; Jaźwiec, B; Klimczak, A; Kołodziej, J; Pacuszko, T; Sedzimirska, M; Tomaszewska-Toporska, B; Tomeczko, J; Was, A1
Masauji, N; Matsue, K; Tohi, T; Tsukuda, K1
Ortlieb, ML; Parkerson, SG; Spitzer, T; Zerbe, MB1
Ambros, P; Emminger, W; Emminger-Schmidmeier, W; Ferstl, G; Fink, FM; Haas, OA; Höcker, P; Mann, G; Peters, C; Urban, C1
Mandelli, F; Meloni, G1
Bierman, PJ; Dennison, JD; Gordon, BG; Klassen, L; Kumar, PP; McGuire, TR; Reed, EC; Sanger, WG; Vaughan, WP; Warkentin, PI1
Emminger, W; Emminger-Schmidmeier, W; Gadner, H; Peters, C1
Bloom, EJ; Buck, DS; Przepiorka, D; Rosenfeld, CS; Schwinghammer, TL; Shadduck, RK1
Jones, RJ; Santos, GW1
Fleischhauer, D; Gassmann, W; Loeffler, H; Müller-Ruchholtz, W; Uharek, L; Wottge, HU1
Cahill, R; Cottler-Fox, M; Deeg, HJ; Greenspan, A; Lynch, M; Spitzer, TR; Torrisi, J1
Gassmann, W; Löffler, H; Mueller-Ruchholtz, W; Schmitz, N; Uharek, L; Wottge, HU1
Blume, KG; Forman, SJ1
Jacobs, P1
Grospietsch, G; Hinney, B; Knappe, G; Kühnle, H; Rümelin, B; Temme, D1
Hodel, C; Zschauer, A1
Asai, T; Asanuma, K; Hiruma, K; Kashimura, M; Nakamura, H; Oh, H; Saito, H; Yoshida, S1
Bullorsky, EO; Ceresetto, JM; Pest, P; Peters, RA; Shanley, CM; Stemmelin, GR1
Crowther, D; Ghielmini, M; Morgenstern, GR; Pettengell, R; Radford, JA; Scheid, C; Stern, PL1
Bernstein, E; Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Mullaney, R; Resnick, K; Styler, MJ; Topolsky, D1
Andersson, BS; Bellare, N; Gajewski, JL; Giralt, SA; Khouri, IF; McCarthy, P; Mehra, R; Nath, R; Przepiorka, D; van Besien, KW1
Bout, M; Brémond, JL; Dayan, A; Delain, M; Domenech, J; Gihana, E; Linassier, C; Petit, A; Petitdidier, C; Truglio, D1
Duława, J; Franek, E; Hołowiecki, J; Kokot, F; Markiewicz, M; Wacławik, A; Wiecek, A; Wojnar, J1
Ashihara, E; Fujita, N; Goto, H; Hirata, T; Inaba, T; Nakagawa, M; Okawa, K; Oku, N; Shimazaki, C; Yamagata, N1
Bélanger, R; Boileau, J; Bonny, Y; Gyger, M; Kassis, J; Lacombe, M; Lavallée, R; Perreault, C; Roy, DC; von Bueltzingsloewen, A1
Adler, SS; Feingold, JM; Ghalie, R; Kaizer, H; Korenblit, AD; Manson, S; Pruett, J; Reynolds, J; Valentino, LA1
Bewermeier, P; Hossfeld, DK; Krüger, W; Mross, K; Reifke, J; Stockschläder, M; Zander, A1
Bewermeier, P; Hossfeld, DK; Krüger, W; Mross, K; Stockschläder, M; Zander, A1
Fujioka, K; Funabiki, T; Ikuta, K; Kai, S; Kajigaya, Y; Matsuyama, S; Sakai, H; Sekiguchi, H; Sumita, H; Takahashi, H1
Cahill, R; Deeg, HJ; Gadner, H; Ortlieb, M; Peters, C; Spitzer, TR; Tefft, MC; Torrisi, J; Urban, C1
Kabisch, H; Kalhs, P; Krüger, W; Lechner, K; Peters, S; Stockschläder, M; Zander, A; Zeller, W1
Damon, LE; Linker, CA; Ries, CA; Rugo, HS; Wolf, JL3
Bulova, SI; Ciobanu, N; Cooper, BW; Creger, RJ; Crilley, P; Fox, RM; Gucalp, R; Lazarus, H; Shina, DC; Topolsky, D1
Tutschka, PJ1
Amylon, MD; Blume, KG; Chao, NJ; Forman, SJ; Long, GD; Negrin, RS; Stein, AS; Wong, RM1
Appelbaum, FR; Blume, KG; Forman, SJ; Henslee-Downey, JP; Kopecky, KJ; LeMaistre, CF; Stiff, PJ1
Ikeda, H; Inoue, T; Masaoka, T; Murayama, S; Ohtani, M; Shibata, H; Song, C; Tang, JT; Teshima, T; Yamazaki, H1
Köpf-Maier, P; Sass, G1
Bettoni, C; Daszkiewicz, P; Ebell, W; Głuszak, B; Kaczmarek-Kanold, M; Lange, A; Malicki, J; Suchnicki, K; Wachowiak, J1
Elfenbein, GJ; Fields, KK; Moscinski, LC; Perkins, JB1
Akiyama, H; Kanda, Y; Onozawa, Y; Sakamaki, H; Sasaki, T; Takamoto, S; Tanikawa, S1
Crowther, D; Deakin, DP; Harris, M; Morgenstern, GR; Pettengell, R; Radford, JA; Ryder, D; Scarffe, JH; Wilkinson, PM; Woll, PJ1
Andrews, F; Bolwell, B; Collins, R; Fay, J; LeFever, A; Levitt, D; List, A; Nemunaitis, J; Pallansch, P; Resta, D; Rosenfeld, CS; Schuster, MW; Taylor, R1
Davidson, TG; Devine, SM; Dix, SP; Geller, RB; Gilmore, CE; Heffner, LT; Hillyer, CD; Holland, HK; Jerkunica, I; Lin, LS; Mullins, RE; Saral, R; Wingard, JR; Winton, EF; York, RC1
Bandini, G; Belardinelli, A; Fiacchini, M; Geromin, A; Gherlinzoni, F; Manfroi, S; Mangianti, S; Miggiano, MC; Motta, MR; Ricci, P; Rizzi, S; Rosti, G; Testoni, N; Tura, S; Visani, G1
Chiusolo, P; Di Mario, A; Leone, G; Micciulli, G; Salutari, P; Sica, S; Tommasi, M1
Agaliotis, DP; Ballester, OF; Elfenbein, GJ; Fields, KK; Goldstein, SC; Hiemenz, JW; Janssen, WE; Perkins, JB; Zorksy, PE1
Appelbaum, FR; Bensinger, WI; Buckner, CD; Chauncey, T; Demirer, T; Fefer, A; Lilleby, K; Petersen, FB; Rowley, S; Sanders, J; Storb, R1
Avalos, BR; Bechtel, TP; Belt, PS; Copelan, EA; Elder, PJ; Ezzone, SA; Hehmeyer, DM; Penza, SL; Scholl, MD1
Bewermeier, P; Hossfeld, DK; Kruger, W; Mross, K; Reifke, J; Zander, A1
Abella, E; Adams, PT; al-Katib, A; Dragovic, J; Du, W; Janakiraman, N; Karanes, C; Raman, SB; Ratanatharathorn, V; Sensenbrenner, L; Silver, SM; Uberti, J; Varterasian, M1
Kortmann, RD1
Akashi, K; Eto, T; Fujisaki, T; Gondo, H; Harada, M; Harada, N; Hayashi, S; Hirota, Y; Kinukawa, N; Makino, S; Matsuishi, E; Miyamoto, T; Mizuno, S; Murakawa, M; Nagafuji, K; Niho, Y; Ohno, Y; Okamura, T; Shibuya, T; Takamatsu, Y; Takenaka, K; Taniguchi, S; Tanimoto, K; Teshima, T; Yamasaki, K1
Becker, AT; Gruppo, RA; Harris, RE; Hashmi, R; Morris, CL; Morris, JD; Sambrano, JE1
Buckner, CD; Rhinehart, S; Schwartzberg, L; Weaver, CH; West, J; West, WH; Zhen, B1
Badri, N; Boogaerts, M; Carella, AM; Dabouz-Harrouche, F; Gautier, L; Gorin, NC; Lennard, A; Link, H; Simonsson, B; Tomas-Martinez, JF1
Boqué, C; Grañena, A1
de Wit, M; Erttmann, R; Hänel, M; Hoffknecht, M; Kabisch, H; Kröger, N; Krüger, W; Stockschläder, M; Weh, HJ; Zander, AR; Zeller, W1
Fukuda, H; Kunitoh, H; Saijo, N; Sekine, I1
Bogusławska-Jaworska, J; Gorczyńska, E; Słociak, M; Toporski, J1
Berger, C; Braumann, D; de Witt, M; Erttmann, R; Fiedler, W; Grimm, J; Horstmann, M; Hossfeld, KD; Illiger, HJ; Kabisch, H; Kröger, N; Krüger, W; Kuse, R; Schönrock, P; Stockshläder, M; Weh, HJ; Zander, AR; Zeller, W1
Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G1
Alvarez Román, MT; Canales Albendea, MA; Hernández Navarro, F; Villanueva Pavón, R1
Bella, S; Burnelli, R; Garaventa, A; Locatelli, F; Melchionda, F; Paolucci, G; Pession, A; Prete, A1
Brodsky, I; Case, D; Crilley, P; Damon, LE; Linker, CA; Navarro, W; Ries, CA; Rubin, A; Rugo, HS; Sayre, P; Topolsky, D; Wolfe, JL; Zamkoff, K1
Berger, HM; Dürken, M; Finckh, B; Fischer, R; Herrnring, C; Kohlschütter, A; Kohlschütter, B; Moison, RM; Nagel, S; Nielsen, P; Pichlmeier, U; Zander, AR1
Bergman, GF; Blumberg, JB; Carlson, JL; Furr, CE; Galloway, JR; Griffith, DP; Jonas, CR; Jones, DP; Puckett, AB; Szeszycki, EE; Tyre, C; Ziegler, TR1
Andresen, SW; Avalos, BR; Bechtel, TP; Bolwell, BJ; Copelan, EA; Elder, PJ; Ezzone, SA; Goormastic, M; Kalaycio, M; O'Donnell, LC; Penza, SL; Pohlman, B; Risley, GL; Scholl, MD; Tighe, MB; Young, DC1
Coppes, MJ; Gamis, A; Hagg, R; Kamani, N; Mustafa, MM; Sandler, ES; Wall, D1
Braumann, D; Colberg, H; del Valle, F; Erttmann, R; Fiedler, W; Finkenstein, F; Holstein, K; Kabisch, H; Kröger, N; Krüger, W; Kuse, R; Mayer, U; Metzner, B; Renges, H; Sonnen, R; Sonnenberg, S; Stute, N; Zabelina, T; Zander, AR1
Bondiau, PY; Foa, C; Magné, N; Otto, J; Thyss, A1
Beijnen, JH; Mathôt, RA; Schellens, JH; van den Bongard, HJ1
Goh, YT; Hwang, YK; Linn, YC; Tan, CH; Tan, HC1
Bilgrami, S; Bona, RD; Clive, J; Edwards, RL; Fox, J; Furlong, F; Kazierad, D; Naqvi, BH; Tutschka, PJ1
Achour, E; Azar, N; Belanger, C; Cassoux, N; Delattre, JY; Gerber, S; Hoang-Xuan, K; Leblond, V; Levy, V; Ribrag, V; Soussain, C; Suzan, F1
Bieri, S; Chapuis, B; Helg, C; Miralbell, R1
Inagawa, H; Kami, M; Kawagoe, S; Kishi, Y; Machida, U; Matsumura, T; Matsushita, H; Miyakoshi, S; Miyazaki, M; Mori, M; Morinaga, S; Muto, Y; Ueyama, J1
Bilgrami, SA; Bona, RD; Clive, J; Edwards, RL; Feingold, JM; Naqvi, B; Tutschka, PJ1
Andresen, S; Bolwell, B; Goormastic, M; Kalaycio, M; Kuczkowski, E; McBee, M; Pohlman, B; Sobecks, R; Wise, K1
Creutzig, U; de Vries, E; Hählen, K; Huismans, DR; Janka-Schaub, GE; Jansen, G; Kaspers, GJ; Peters, GJ; Pieters, R; Rots, MG; van Zantwijk, CH; Veerman, AJ; Zwaan, CM1
Aulagner, G; Bertrand, Y; Bleyzac, N; Dai, Q; Galambrun, C; Janoly, A; Jelliffe, RW; Magron, P; Maire, P; Martin, P; Souillet, G1
Arcese, W; Cerretti, R; De Felice, L; Donato, V; Fenu, S; Guglielmi, C; Iori, A; Laurenti, L; Mengarelli, A; Micozzi, A; Romano, A; Torromeo, C1
Thigpen, T1
Case, D; Damon, LE; Linker, CA; Navarro, WA; Ries, CA; Wolf, JL1
Birkmann, J; Bornhäuser, M; Ehninger, G; Fiedler, F; Hänel, A; Hänel, M; Hoffknecht, MM; Kröger, N; Kroschinsky, F; Krüger, W; Metzner, B; Schmid, B; Sonnenberg, S; Zander, AR1
Arai, T; Hanada, R; Ida, K; Inatomi, J; Kawaguchi, H; Kikuchi, A; Kishimoto, H; Oh-Ishi, T; Taketani, T; Yamamoto, K1
Al-Jefri, A; Al-Mahr, M; Ayas, M; Belgaumi, A; Leung, W; Solh, H1
Armata, J; Balcerska, A; Bogusławska-Jaworska, J; Boruczkowski, D; Bubała, H; Chybicka, A; Cwiklińska, M; Hicke, A; Kaczmarek-Kanold, M; Kałwak, K; Kolecki, P; Kowalczyk, J; Krauze, A; Matysiak, M; Płoszyńska, A; Rokicka-Milewska, R; Sikorska-Fic, B; Sońta-Jakimczyk, D; Staszak-Kowalska, R; Tomaszewska, R; Turkiewicz, D; Wachowiak, J; Wiśniewska-Slusarz, H; Wysocki, M1
Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J1
Grigg, AP; Ritchie, DS; Roberts, AW; Shuttleworth, P; Szer, J1
Fedier, A; Fink, D; Haller, U; Lenherr, L; Schwarz, VA; Steiner, RA1
Cogle, CR; Finiewicz, KJ; Khan, SA; Leather, HL; Moreb, JS; Reddy, VS; Wingard, JR1
Fujii, S; Fujino, H; Hino, M; Hirai, M; Inoue, T; Sako, M; Teshima, H; Yagi, T1
Fouillard, L; Frassoni, F; Gorin, NC; Labopin, M; Meloni, G; Polge, E1
Hoang-Xuan, K; Levy, V; Soussain, C1
Becker, E; Casper, J; Franke, A; Freund, M; Heim, M; Jentsch-Ullrich, K; Koenigsmann, M; Mohren, M1
Andresen, S; Ball, E; Bolwell, B; Cook, D; Kalaycio, M; Kuczkowski, E; Pohlman, B; Rybicki, L; Sobecks, R1
Avalos, BR; Blum, W; Bolwell, BJ; Byrd, JC; Copelan, E; Elder, PJ; Farag, SS; Kalaycio, M; Lin, T; Marcucci, G; Penza, S; Pohlman, B; Sobecks, R1
Rao, PS1
Behringer, D; Bertz, H; Finke, J; Küttler, T; Samek, E; Spyridonidis, A; Wäsch, R; Waterhouse, M1
Alapetite, C; Anract, P; Babinet, A; Barthier, S; de Pinieux, G; Laurence, V; Palangié, T; Pierga, JY; Pouillart, P1
Al-Jefri, A; Al-Mahr, M; Al-Seraihi, A; Ayas, M; Belgaumi, A; El-Solh, H; Elhassan, I1
Driver, D; Kilby, AM; McTiernan, A; Michelagnoli, MP; Whelan, JS1
Aggarwal, C; Carabasi, MH; Gupta, S; Katz, RO; Nance, AG; Salzman, DE; Saylors, GB; Tilden, AB; Vaughan, WP1
Avalos, B; Benson, DM; Blum, W; Copelan, E; Elder, PJ; Farag, SS; Lin, TS; Penza, S1
Chantry, AD; Craddock, C; Craig, JI; Marks, DI; Orchard, K; Pearce, RM; Peggs, K; Roddie, C; Snowden, JA; Towlson, KE1
Andrèsen, S; Avalos, B; Bolwell, B; Copelan, E; Elder, P; Farag, S; Kalaycio, M; Lin, T; Marcucci, G; Penza, S; Pohlman, B; Sobecks, R; Wadehra, N1
Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S1
Andresen, S; Bolwell, BJ; Brown, S; Dean, R; Hsi, ED; Kalaycio, M; Pohlman, B; Rybicki, LA; Smith, SD; Sobecks, R; Sweetenham, JW1
Flowers, C; Hutcherson, D; Langston, A; Santos, EC; Sessions, J; Waller, EK1
Bae, SH; Chae, YS; Eom, HS; Jung, JS; Kim, DH; Kim, HJ; Kim, JG; Kim, SJ; Kim, WS; Lee, JJ; Shin, HJ; Sohn, SK; Suh, C; Yang, DH1
Fujioka, K; Funabiki, T; Goto, H; Goto, S; Hanzawa, N; Ikuta, K; Izaki, S; Kai, S; Matsuda, M; Okuda, K; Sasaki, H; Sekiguchi, H; Sumita, H; Takahashi, H; Watanabe, Y; Yokota, S1
Casasnovas, O; Choquet, S; Dupriez, B; Fourme, E; Gisselbrecht, C; Hoang-Xuan, K; Jaccard, A; Janvier, M; Kolb, B; Leblond, V; Omuro, A; Sanson, M; Souleau, B; Soussain, C; Taillandier, L; Taksin, AL; Witz, F; Zini, JM1
Baer, MR; Baldus, CD; Bloomfield, CD; Caligiuri, MA; Carroll, AJ; Kolitz, JE; Langer, C; Larson, RA; Maharry, K; Marcucci, G; Mrózek, K; Paschka, P; Powell, BL; Ruppert, AS; Whitman, SP; Zhao, W1
Amoroso, L; Benhamou, E; Cacchione, A; Couanet, DV; Hartmann, O; LeMaitre, A; Simonnard, N1
Bai, CH; Kim, YD; Song, SY; Woo, HJ1
Acebo, E; Díaz-Pérez, JL; García-Ruiz, JC; Izu, R; Martínez de Lagrán, Z; Pérez-Barrio, S1
Bensinger, WI; Gooley, T; Gopal, AK; Holmberg, L; Maloney, D; Press, O; Zaucha, R1
Choi, YH; Huh, J; Jang, G; Kang, BW; Kim, C; Kim, S; Kim, SW; Kim, WS; Lee, DH; Lee, JS; Lee, SS; Ryu, JS; Suh, C1
Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P1
Andresen, S; Bolwell, BJ; Copelan, EA; Curtis, J; Dean, RM; Kalaycio, ME; Pohlman, B; Rybicki, LA; Smith, SD; Sobecks, RM; Sweetenham, JW1
Forman, SJ; Karanes, C; Kogut, N; Krishnan, AY; Nademanee, A; Nakamura, R; O'Donnell, M; Palmer, JM; Parker, P; Pullarkat, V; Rodriguez, R; Rosenthal, J; Senitzer, D; Shayani, S; Smith, E; Snyder, D1
Choi, DR; Huh, J; Kim, S; Kim, SW; Lee, DH; Lee, JS; Lee, SW; Sohn, BS; Suh, C; Yoon, DH1
Arai, S; Blume, K; Brown, J; Johnston, L; Laport, G; Lowsky, R; Miklos, D; Naik, S; Negrin, R; Shizuru, J; Wong, R1
Huh, J; Kim, JE; Kim, S; Kim, SW; Lee, DH; Lee, JS; Park, CJ; Suh, C; Yoo, C1
Esiashvili, N; Flowers, C; Kahn, S; Xu, Z1
Alberghini, M; Alvegard, TA; Bacci, G; Barbieri, E; Brach Del Prever, A; Capanna, R; Carli, M; Fagioli, F; Ferrari, S; Gandola, L; Luksch, R; Mapelli, S; Mercuri, M; Picci, P; Prete, A; Smeland, S; Sundby Hall, K; Tamburini, A; Tienghi, A; Wiebe, T1
Alvarnas, JC; Dagis, AC; Forman, SJ; Nademanee, AP; O'Donnell, MR; Parker, PM; Pullarkat, VA; Snyder, DS; Spielberger, RT; Stein, AS; Synold, TW; Thomas, SH; Tsirunyan, A; Wong, JY1
Anson, J; Gollard, RP; Khoury, J; Mason, J; Rosen, L1
Choma, M; Chybicka, A; Cornish, J; Gorczyńska, E; Grund, G; Kowalczyk, JR; Peters, C; Sykora, KW; Wachowiak, J1
Fanti, PA; Misciali, C; Miteva, M; Romanelli, P; Tosti, A; Vincenzi, C1
Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C1
Belinka, BA; Gupta, A; Kachlany, SC; Le, A1
Delioukina, M; Forman, SJ; Gaal, K; Kogut, N; Nademanee, A; O'Donnell, M; Palmer, JM; Popplewell, L; Senitzer, D; Thomas, S; Tsai, NC; Zain, J1
Boos, J; Hempel, G; Kersting, G; Lippert, J; Willmann, S; Würthwein, G1
Bahlis, NJ; Carlson, L; Duan, Q; Duggan, P; Hasegawa, W; Russell, JA; Stewart, DA; Voralia, M1
Bargetzi, M; Cornelissen, JJ; Ferrant, A; Fey, MF; Gratwohl, A; Graux, C; Huijgens, PC; Löwenberg, B; Maertens, J; Ossenkoppele, GJ; Schaafsma, R; Schanz, U; Schouten, HC; Theobald, M; van Putten, W; Vellenga, E; Verdonck, LF1
Al-Ahmari, A; Al-Jefri, A; Al-Nounou, R; Al-Seraihy, A; Ayas, M; Belgaumi, A; El-Solh, H1
Furuya, T; Ikeda, T; Inoue, M; Kaneda, H; Koshinaga, T; Maebayashi, T; Masuko, T; Mugishima, H; Ohashi, K; Sugito, K; Yagasaki, H1
Ali, Z; Dada, MO; Flowers, CR; Graiser, M; Hutcherson, DA; McMillan, S; Waller, EK; Zhang, H1
Forman, S; Liu, A; Palmer, J; Radany, E; Rosenthal, J; Schultheiss, T; Somlo, G; Stein, A; Wong, JY1
Abate, ME; Barbieri, E; Bisogno, G; Daolio, P; Eriksson, M; Fagioli, F; Ferrari, S; Gandola, L; Grignani, G; Hall, KS; Lindholm, P; Luksch, R; Picci, P; Podda, M; Prete, A; Ruggieri, P; Smeland, S; Tamburini, A; Tienghi, A1
Alimoghaddam, K; Bahar, B; Behfar, M; Ghavamzadeh, A; Hamdi, A; Hamidieh, AA; Iravani, M; Jahani, M; Jalali, A; Jalili, M; Mousavi, SA1
Ahmed, AB; Bruserud, O; Hatfield, KJ; Kittang, AO; Reikvam, H; Sjo, M; Tvedt, TH1
Boldrini, R; Castellano, A; Contoli, B; Corneli, T; Crocoli, A; DE Ioris, MA; DE Pasquale, MD; DE Sio, L; Garganese, MC; Jenkner, A; Pessolano, R; Serra, A1
Fan, ZP; Huang, F; Jiang, QL; Liu, QF; Meng, FY; Sun, J; Wei, YQ; Wu, MQ; Wu, XL; Xu, D; Yu, GP; Zhang, Y; Zhao, J1
Ahn, JS; Chae, YS; Jung, SH; Kim, HJ; Kim, YK; Kwak, JY; Lee, JJ; Lee, SR; Sohn, SK; Yang, DH; Yhim, HY1
Du, J; Fan, JL; Fu, WJ; Hou, J; Jiang, H; Jin, LN; Li, R; Xi, H; Zeng, TM; Zhang, CY; Zhou, LL1
Andreadis, C; Giacomini, KM; Kubo, M; Matsuda, K; Mefford, JA; Percival, ME; Singh, N; Stecula, A; Takahashi, A; Witte, JS; Yang, K; Yee, SW1
Akashi, K; Eto, T; Gondo, H; Harada, M; Kamimura, T; Miyamoto, T; Nagafuji, K; Ohno, Y; Takamatsu, Y; Takase, K; Taniguchi, S; Teshima, T1
Balleisen, L; Basara, N; Behre, G; Casper, J; Christopeit, M; Ganser, A; Hinke, A; Hinke, R; Kahl, C; Koenigsmann, M; Metzner, B; Mohren, M; Niederwieser, D; Reichle, A; Sayer, HG; Stadler, M; Theurich, S; Uharek, L1
Chung, JS; Kim, H; Kim, JS; Lee, GW; Lee, HS; Lee, WS; Shin, HJ; Song, MK; Yhim, HY1
Bubalo, J; Carpenter, PA; Leather, HL; Majhail, N; Marks, DI; Perales, MA; Pidala, J; Savani, BN; Shaughnessy, P; Wingard, J1
Forman, SJ; Kim, JH; Liu, A; Palmer, J; Rosenthal, J; Schultheiss, TE; Stein, A; Tsai, N; Wong, JY1
Akpek, G; Aljurf, M; Artz, A; Bredeson, CN; Chen, YB; Cooke, KR; Ho, VT; Lane, AA; Lazarus, HM; Logan, B; McCarthy, P; Olsson, R; Pasquini, MC; Saber, W; Zhu, X1
Ai, WZ; Andreadis, C; Benet, LZ; Damon, LE; Gaensler, KM; Kaplan, LD; Koplowicz, YB; Linker, CA; Logan, AC; Mannis, GN; Martin, TG; Olin, RL; Sayre, PH; Smith, CC; Sudhindra, A; Venstrom, JM; Wolf, JL1
Arnold, R; Ayuk, F; Beelen, D; Bethge, W; Bornhäuser, M; Gökbuget, N; Heinzelmann, M; Hölzer, D; Kobbe, G; Kröger, N; Martin, H; Meyer, RG; Pichlmeier, U; Schmid, C; Stelljes, M; Trenschel, R; Wolschke, C; Zander, A1
Elborai, Y; Elhaddad, A; Hafez, H; Hammad, M; Hussein, H; Lehmann, L; Moussa, EA1
Aplenc, R; Bagatell, R; Desai, AV; Fisher, BT; Getz, K; Huang, V; Li, Y; Mante, A; Seif, AE1
Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF1
Bagatell, R; Bunin, NJ; Desai, AV; Grupp, SA; Heneghan, MB; Li, Y; Seif, AE1
Andresen, S; Bolwell, BJ; Carlstrom, KD; Dean, R; Gerds, A; Hamilton, B; Hill, BT; Jagadeesh, D; Kalaycio, M; Liu, H; Majhail, NS; Pohlman, B; Rybicki, L; Sobecks, R1
Bruno, B; Chalandon, Y; Charbonnier, A; Coiteux, V; Simon, N; Souchet, L; Taque, S; Vincent, L; Yakoub-Agha, I1
Boddy, AV; Chatelut, E; Osborne, C; Paci, A; Veal, GJ; White-Koning, M1
Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Ma, J; Milgrom, S; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shpall, EJ; Thall, PF; Timmons, M; Valdez, BC1
Aplenc, R; Bagatell, R; Desai, AV; Fisher, B; Getz, K; Huang, V; Li, Y; Seif, AE1
Baker, KS; Carpenter, PA; El-Haddad, A; Elzembely, MM; Park, JR; Pinto, N; Riad, KF; Sayed, HA1
Chen, J; Huang, H; Jiang, Y; Jin, Z; Liu, S; Ruan, J; Wu, D; Xiao, X; Zhang, L; Zhang, X1
Abounader, D; Andritsos, L; Benson, DM; Bolwell, B; Dean, R; Devine, SM; Efebera, YA; Elder, P; Hill, B; Hofmeister, CC; Jagadeesh, D; Jaglowski, S; Kalaycio, M; Majhail, NS; Penza, S; Pohlman, B; Rosko, A; Sharma, N; Singer, S; Sobecks, R; Vasu, S; William, BM; Zhao, Q1
Hong, JY; Huh, J; Hyung, J; Kim, JH; Kim, S; Lee, SW; Park, CS; Park, JS; Ryu, JS; Suh, C; Yoon, DH1
Anderton, J; Brennan, B; Evans, A; Fenwick, N; Fernández-Pinto, M; Gaspar, N; Gelderblom, H; Kaiser, S; Laurence, V; Marec-Bérard, P; Martín-Broto, J; Moroz, V; Owens, C; Sastre, A; Strauss, S; Wheatley, K; Whelan, J1
Cho, SH; Chung, JS; Jo, JC; Kim, DY; Shin, HJ1
Eich, HT; Scobioala, S1
Bae, SH; Choi, Y; Jo, JC; Kim, IH; Kim, JS; Lee, JH; Lee, SM; Lee, WS; Lee, YJ; Lim, SN; Yoon, SS1
Arakawa, Y; Hiwatari, M; Hogetsu, K; Kato, S; Koh, K; Kubota, Y; Takita, J; Watanabe, K1
Aleinikova, O; Ansari, M; Ariffin, H; Bader, P; Balduzzi, A; Bierings, M; Buechner, J; Burkhardt, B; Corbacioglu, S; Dalle, JH; Diaz-de-Heredia, C; Essa, M; Güngör, T; Ifversen, M; Lankester, A; Locatelli, F; Meisel, R; Peters, C; Pichler, H; Poetschger, U; Schrappe, M; Schultz, K; Sedlacek, P; Shaw, PJ; Staciuk, R; Stein, J; Svec, P; Toporski, J; Truong, TH; Vettenranta, K; von Stackelberg, A1
Bas, EG; Celen, S; Daloglu, H; Hazar, V; Kabakci, C; Karasu, GT; Pashayev, D; Pehlivan, B; Uygun, V; Yalcin, K; Yesilipek, A; Zhumatayev, S1
de Lima, VCC; Filho, JS; Germano, JN; Matias Vieira, GM; Moura, FL; Sapelli, J1
Chen, J; Fan, S; Jiang, F; Liu, X; Liu, Z; Sun, Y; Xiao, J1
Barnett, S; Bérénos, IM; Carruthers, V; Huitema, ADR; Kong, J; Lalmohamed, A; Nijstad, AL; Parke, E; Tweddle, DA; Veal, GJ; Zwaan, CM1
Do, YR; Kang, HJ; Kim, HG; Kim, KH; Kim, WS; Kong, JH; Kwak, JY; Lee, JH; Lee, M; Mun, YC; Oh, SY; Park, MR; Park, SK; Park, Y; Shin, HJ; Won, JH; Yang, DH1
Abraham, J; Agbetiafa, K; Ahle, G; Bonmati, C; Bouabdallah, K; Bouabdallah, R; Bourget, P; Casasnovas, O; Charron, C; Chauchet, A; Chinot, O; Choquet, S; Cornillon, J; Damaj, G; Delwail, V; Dorvaux, V; Fabbro, M; Fornecker, LM; Ghesquières, H; Giordan, Q; Gressin, R; Gyan, E; Hoang-Xuan, K; Houillier, C; Houot, R; Jabeur, W; Jardin, F; Le Garff-Tavernier, M; Malaise, D; Marolleau, JP; Moluçon-Chabrot, C; Morschhauser, F; Nichelli, L; Oberic, L; Peyrade, F; Plessier, A; Roland, V; Schenone, L; Schmitt, A; Soussain, C; Taillandier, L; Tanguy, ML; Tempescul, A; Thieblemont, C; Touitou, V; Ursu, R; Wantz-Mézières, S; Waultier-Rascalou, A; Willems, L1
Bauer, S; Baumhoer, D; Bernkopf, M; Bhadri, V; Bonar, F; Bovee, J; Brichard, B; Burdach, S; Butterfaß-Bahloul, T; Collaud, S; Cyprova, S; Dhooge, C; Dirksen, U; Egerer, G; Eich, HT; Ek, T; Faldum, A; Gelderblom, H; Hardes, J; Hartmann, W; Hassenpflug, W; Hauser, P; Haveman, L; Hjorth, L; Hong, A; Jürgens, H; Kanerva, J; Kessler, T; Kiss, J; Koch, R; Kruseova, J; Kühne, T; Metzler, M; Paulussen, M; Raciborska, A; Ranft, A; Rascon, J; Reichardt, P; Renard, M; Timmermann, B; van den Berg, H; Vieth, V1
Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S1
Albert, MH; Bader, P; Basu, O; Beier, R; Burkhardt, B; Classen, CF; Claviez, A; Corbacioglu, S; Deubzer, HE; Eichinger, A; Glogova, E; Greil, J; Gruhn, B; Güngör, T; Kafa, K; Kühl, JS; Lang, P; Lange, BS; Meisel, R; Müller, I; Peters, C; Poetschger, U; Sauer, MG; Schlegel, PG; Schulz, A; Stachel, D; Strahm, B; Wawer, A1
Brennan, B; Fenwick, N; Gaspar, N; Gelderblom, H; Kirton, L; Laurence, V; Marec-Bérard, P; Martín-Broto, J; Moroz, V; Owens, C; Sastre, A; Strauss, S; Wheatley, K; Whelan, J1
Arcese, W; Ciceri, F; Gedde-Dahl, T; Gorin, NC; Labopin, M; Lanza, F; Maertens, J; Meijer, E; Mohty, M; Montoro, J; Pabst, T; Pérez-Simón, JA; Sanz, J; Schaap, N; Van Gorkom, G; Versluis, J; Vrhovac, R1

Reviews

15 review(s) available for etoposide and busulfan

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Conditioning regimens for allogeneic bone marrow transplantation.
    Blood reviews, 1992, Volume: 6, Issue:4

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Humans; Leukemia; Lymphocyte Depletion; Melphalan; T-Lymphocytes; Transplantation, Homologous; Whole-Body Irradiation

1992
[Allogeneic bone marrow transplantation in myeloid leukemia: chemical conditioning, clinical course and results].
    Acta haematologica Polonica, 1992, Volume: 23, Issue:2 Suppl 1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Graft Enhancement, Immunologic; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Transplantation, Homologous

1992
Use of busulfan containing chemotherapy for conditioning patients with leukemia for bone marrow allografting.
    Bone marrow transplantation, 1993, Volume: 12 Suppl 1

    Topics: Actuarial Analysis; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytokines; Etoposide; Graft vs Host Disease; Humans; Leukemia; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Syndrome; Treatment Outcome; Whole-Body Irradiation

1993
High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts.
    Annals of the New York Academy of Sciences, 1995, Dec-29, Volume: 770

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carboplatin; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Taxoids; Thiotepa

1995
[Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia].
    Sangre, 1998, Volume: 43, Issue:2

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Component Removal; Busulfan; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fusion Proteins, bcr-abl; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Ifosfamide; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

1998
Cancer chemotherapy in the elderly.
    Japanese journal of clinical oncology, 1998, Volume: 28, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Busulfan; Daunorubicin; Doxorubicin; Etoposide; Female; Fluorouracil; Heart; Hematologic Neoplasms; Humans; Lung; Male; Middle Aged; Neoplasms; Pyrazoles

1998
Pharmacokinetically guided administration of chemotherapeutic agents.
    Clinical pharmacokinetics, 2000, Volume: 39, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Carboplatin; Cisplatin; Etoposide; Fluorouracil; Humans; Topotecan

2000
The role of gemcitabine-based doublets in the management of ovarian carcinoma.
    Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine

2002
Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.
    American journal of clinical oncology, 2005, Volume: 28, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Carmustine; Cisplatin; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Life Tables; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prognosis; Retrospective Studies; Risk Factors; Sarcoma, Ewing; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine

2005
High-dose etoposide in allogeneic stem cell transplantation.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:6

    Topics: Adenine Nucleotides; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Busulfan; Carboplatin; Carmustine; Clinical Trials as Topic; Clofarabine; Cyclophosphamide; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Leukemia; Leukemia, Myeloid, Acute; Lomustine; Mucositis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy, Adjuvant; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation

2012
Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:5

    Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Dosage Calculations; Etoposide; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Myeloablative Agonists; Obesity; Transplantation Conditioning

2014
[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-T
    Bulletin du cancer, 2017, Volume: 104, Issue:12S

    Topics: Adult; Age Factors; Busulfan; Child; Comorbidity; Cyclophosphamide; Etoposide; France; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Liver Diseases; Melphalan; Obesity; Renal Insufficiency, Chronic; Societies, Medical; Surveys and Questionnaires; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2017
Risk stratification of pulmonary toxicities in the combination of whole lung irradiation and high-dose chemotherapy for Ewing sarcoma patients with lung metastases: a review.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2020, Volume: 196, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modality Therapy; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Drug Administration Schedule; Etoposide; Female; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Melphalan; Procedures and Techniques Utilization; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Respiratory Function Tests; Risk; Sarcoma, Ewing; Whole-Body Irradiation; Young Adult

2020
Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 164

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Etoposide; Humans; Infant; Infant, Newborn

2022

Trials

51 trial(s) available for etoposide and busulfan

ArticleYear
[Autotransplantation in acute nonlymphoid leukemia].
    Haematologica, 1991, Volume: 76 Suppl 3

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Remission Induction; Transplantation, Autologous

1991
Busulphan versus combination chemotherapy for initial treatment of chronic granulocytic leukaemia.
    American journal of hematology, 1986, Volume: 22, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects

1986
Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion.
    Bone marrow transplantation, 1994, Volume: 13, Issue:4

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Gastrointestinal Diseases; Hodgkin Disease; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Stomatitis

1994
[High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1993, Volume: 34, Issue:5

    Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Nimustine

1993
Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia.
    Blood, 1993, Jan-15, Volume: 81, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Recurrence; Survival Analysis; Time Factors; Transplantation, Autologous

1993
A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.
    Blood, 1993, Apr-15, Volume: 81, Issue:8

    Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Prospective Studies; Remission Induction; Risk Factors; Whole-Body Irradiation

1993
Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia.
    Acta haematologica Polonica, 1995, Volume: 26, Issue:4

    Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate; Whole-Body Irradiation

1995
Etoposide with/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation. The BMT Team.
    American journal of hematology, 1996, Volume: 51, Issue:4

    Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Administration Schedule; Drug Synergism; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hepatic Veno-Occlusive Disease; Humans; Hyperbilirubinemia; Immunologic Factors; Leukemia, Myeloid; Leukopenia; Male; Middle Aged; Premedication; Salvage Therapy

1996
Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Prednisolone; Prognosis; Survival Rate; Transplantation, Autologous; Vincristine

1996
Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
    Bone marrow transplantation, 1996, Volume: 17, Issue:2

    Topics: Adult; Bone Marrow; Breast Neoplasms; Busulfan; Carboplatin; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug Synergism; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Interleukin-3; Leukapheresis; Leukemia; Leukocyte Count; Lymphoma; Male; Middle Aged; Neutrophils; Prospective Studies; Thiotepa; Whole-Body Irradiation

1996
Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
    Leukemia, 1996, Volume: 10, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Prognosis; Proportional Hazards Models; Remission Induction; Survival Rate; Time Factors; Transplantation, Autologous

1996
Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
    Bone marrow transplantation, 1996, Volume: 18, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Life Tables; Lung Diseases, Interstitial; Male; Middle Aged; Neutropenia; Remission Induction; Treatment Outcome

1996
Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant.
    American journal of clinical oncology, 1997, Volume: 20, Issue:5

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Carmustine; Cause of Death; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation

1997
Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia.
    Bone marrow transplantation, 1997, Volume: 20, Issue:10

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukocyte Count; Life Tables; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Proportional Hazards Models; Prospective Studies; Remission Induction; Treatment Outcome

1997
High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
    Bone marrow transplantation, 1998, Volume: 21, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Transplantation, Autologous

1998
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:12 Pt 2

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Male; Methotrexate; Methylprednisolone; Middle Aged; Remission Induction; Time Factors; Transplantation, Homologous

1997
Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.
    Medical and pediatric oncology, 1999, Volume: 33, Issue:5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Neuroblastoma; Prognosis; Rhabdomyosarcoma; Sarcoma, Ewing; Thiotepa

1999
Autologous stem cell transplantation for acute myeloid leukemia in first remission.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2000, Volume: 6, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytapheresis; Cytarabine; Cytogenetics; Disease-Free Survival; Etoposide; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukocyte Count; Middle Aged; Recurrence; Survival Rate; Transplantation, Autologous

2000
Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients.
    The American journal of clinical nutrition, 2000, Volume: 72, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Ascorbic Acid; Bone Marrow Neoplasms; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Etoposide; Female; Glutathione; Glutathione Peroxidase; Humans; Male; Middle Aged; Parenteral Nutrition, Total; Vitamin E; Zinc

2000
Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma.
    Bone marrow transplantation, 2000, Volume: 25, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Survival Analysis; Transplantation, Autologous

2000
Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium.
    Medical and pediatric oncology, 2000, Volume: 35, Issue:4

    Topics: Adolescent; Alberta; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Missouri; Texas; Transplantation Conditioning; Treatment Outcome

2000
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Feb-01, Volume: 19, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Eye Neoplasms; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Salvage Therapy; Thiotepa

2001
Cytoreduction and stem cell mobilization with a regimen of paclitaxel, etoposide and cyclophosphamide followed by autologous transplantation using a preparative regimen of busulfan, etoposide and cyclophosphamide for patients with advanced lymphoma.
    Acta haematologica, 2001, Volume: 105, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis; Transplantation, Autologous

2001
A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation.
    Bone marrow transplantation, 2002, Volume: 30, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Mucous Membrane; Stomatitis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous

2002
High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation.
    Bone marrow transplantation, 2004, Volume: 34, Issue:6

    Topics: Adult; Antineoplastic Agents, Alkylating; Busulfan; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Middle Aged; Recurrence; Stem Cell Transplantation; Transplantation, Autologous

2004
CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Bone marrow transplantation, 2005, Volume: 35, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; CD8-Positive T-Lymphocytes; Cyclophosphamide; Etoposide; Female; Graft Survival; Graft vs Host Disease; Histocompatibility; Histocompatibility Testing; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Salvage Therapy; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2005
High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.
    Bone marrow transplantation, 2005, Volume: 35, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Survival Analysis; Transplantation, Homologous; Treatment Outcome

2005
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-20, Volume: 26, Issue:15

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Eye Neoplasms; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Survival Rate; Thiotepa

2008
Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Investigational new drugs, 2010, Volume: 28, Issue:4

    Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Male; Middle Aged; Secondary Prevention; Transplantation Conditioning; Transplantation, Autologous

2010
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
    Blood, 2010, Feb-04, Volume: 115, Issue:5

    Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Pilot Projects; Radiation Dosage; Siblings; Sirolimus; Survival Analysis; Tacrolimus; Thrombotic Microangiopathies; Tissue Donors; Transplantation Conditioning; Vidarabine; Young Adult

2010
Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience.
    Bone marrow transplantation, 2011, Volume: 46, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous

2011
BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
    Leukemia research, 2011, Volume: 35, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult

2011
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Melphalan; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Sarcoma, Ewing; Vincristine; Young Adult

2011
Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemia.
    Bone marrow transplantation, 2011, Volume: 46, Issue:9

    Topics: Adult; Busulfan; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Recurrence; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation; Young Adult

2011
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
    Bone marrow transplantation, 2011, Volume: 46, Issue:12

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Neoplasms; Humans; Infant; Male; Melphalan; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2011
A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Prospective Studies; Quality of Life; Rituximab; Survival Rate; Transplantation Conditioning; Vidarabine

2011
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.
    Blood, 2011, Dec-01, Volume: 118, Issue:23

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Prognosis; Prospective Studies; Remission Induction; Transplantation, Autologous; Treatment Outcome; Young Adult

2011
Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation.
    International journal of radiation oncology, biology, physics, 2013, Jan-01, Volume: 85, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Liver; Male; Middle Aged; Organs at Risk; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy Dosage; Recurrence; Stomatitis; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation; Young Adult

2013
Comparison of two different conditioning regimens before autologous transplantation for children with high-risk neuroblastoma.
    Anticancer research, 2012, Volume: 32, Issue:12

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Gene Amplification; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Risk Factors; Thiotepa; Transplantation Conditioning

2012
Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.
    Bone marrow transplantation, 2014, Volume: 49, Issue:3

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Disease Progression; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Risk Factors; Rituximab; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Young Adult

2014
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
    International journal of radiation oncology, biology, physics, 2014, May-01, Volume: 89, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Melphalan; Middle Aged; Myelodysplastic Syndromes; Organ Sparing Treatments; Organs at Risk; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Radiotherapy Dosage; Recurrence; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2014
A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:6

    Topics: Administration, Intravesical; Adult; Area Under Curve; Busulfan; Disease-Free Survival; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Mucositis; Myeloablative Agonists; Recurrence; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2015
Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL).
    Bone marrow transplantation, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Adult; Allografts; Busulfan; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stem Cell Transplantation; Transplantation Conditioning

2015
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:7

    Topics: Adult; Aged; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; North America; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous

2016
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Deoxycytidine; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Middle Aged; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Young Adult

2018
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol.
    Trials, 2020, Jan-17, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Busulfan; Child; Child, Preschool; Consolidation Chemotherapy; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Induction Chemotherapy; Male; Middle Aged; Sarcoma, Ewing; Vincristine; Young Adult; Zoledronic Acid

2020
Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma.
    Annals of hematology, 2020, Volume: 99, Issue:4

    Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Busulfan; Combined Modality Therapy; Etoposide; Febrile Neutropenia; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Premedication; Progression-Free Survival; Prospective Studies; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2020
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 02-01, Volume: 39, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoradiotherapy; Child; Child, Preschool; Equivalence Trials as Topic; Etoposide; Female; Follow-Up Studies; Humans; International Agencies; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Thiotepa; Vidarabine; Whole-Body Irradiation

2021
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Mul
    Cancer research and treatment, 2023, Volume: 55, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Behavior Therapy; Busulfan; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Transplantation, Autologous

2023
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 07-20, Volume: 40, Issue:21

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Consolidation Chemotherapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Male; Melphalan; Prospective Studies; Sarcoma, Ewing; Vincristine

2022
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
    Lancet (London, England), 2022, 10-29, Volume: 400, Issue:10362

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Ifosfamide; Melphalan; Sarcoma, Ewing; Vincristine

2022

Other Studies

137 other study(ies) available for etoposide and busulfan

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Synthesis and induction of G0-G1 phase arrest with apoptosis of 3,5-dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4(3H)-one.
    European journal of medicinal chemistry, 2008, Volume: 43, Issue:11

    Topics: Apoptosis; Azepines; G1 Phase; HL-60 Cells; Humans; K562 Cells; Molecular Structure; Pyrazoles; Resting Phase, Cell Cycle

2008
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
[Second marrow transplantation following high dose busulfan, etoposide, and Ara-C after testicular relapse in a patient with AML].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1992, Volume: 33, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Testicular Neoplasms

1992
Relationships between oral mucositis and treatment variables in bone marrow transplant patients.
    Cancer nursing, 1992, Volume: 15, Issue:3

    Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; District of Columbia; Etoposide; Female; Hospitals, University; Humans; Male; Middle Aged; Nursing Assessment; Pilot Projects; Risk Factors; Severity of Illness Index; Stomatitis; Whole-Body Irradiation

1992
Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation.
    Bone marrow transplantation, 1992, Volume: 9, Issue:5

    Topics: Bone Marrow Transplantation; Busulfan; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Graft vs Host Disease; Hematopoiesis; Humans; Incidence; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma

1992
Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
    Bone marrow transplantation, 1991, Volume: 8, Issue:6

    Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Incidence; Leukemia; Middle Aged; Time Factors; Transplantation, Homologous

1991
Influence of immunosuppression on acute liver toxicity after intensified conditioning regimens for bone marrow transplantation in children.
    Blood, 1991, Apr-01, Volume: 77, Issue:7

    Topics: Bone Marrow Transplantation; Busulfan; Child; Cyclosporins; Drug Therapy, Combination; Etoposide; Graft vs Host Disease; Humans; Immunosuppression Therapy; Leukemia; Liver; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Transplantation, Autologous; Whole-Body Irradiation

1991
Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease.
    Experimental hematology, 1991, Volume: 19, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Dose-Response Relationship, Drug; Etoposide; Female; Hodgkin Disease; Humans; Infusion Pumps; Lymphoma, Non-Hodgkin; Male; Middle Aged; Transplantation, Autologous

1991
New conditioning regimens for high risk marrow transplants.
    Bone marrow transplantation, 1989, Volume: 4 Suppl 4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporins; Drug Evaluation; Etoposide; Graft vs Host Disease; Humans; Leukemia; Lymphoma; Middle Aged

1989
Comparison of immunosuppressive agents for prevention of graft rejection in allogeneic bone marrow transplantation.
    Transplantation proceedings, 1989, Volume: 21, Issue:1 Pt 3

    Topics: Animals; Bone Marrow Transplantation; Busulfan; Cytarabine; Etoposide; Graft Rejection; Immunosuppressive Agents; Postoperative Complications; Preoperative Care; Rats; Rats, Inbred Lew; Whole-Body Irradiation

1989
Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
    Bone marrow transplantation, 1989, Volume: 4, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Leukemia; Middle Aged; Whole-Body Irradiation

1989
Comparison of cyclophosphamide, cytarabine, and etoposide as immunosuppressive agents before allogeneic bone marrow transplantation.
    Blood, 1988, Volume: 72, Issue:5

    Topics: Animals; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Radiation; Etoposide; Graft Survival; Immunosuppression Therapy; Rats; Rats, Inbred Strains; Skin Transplantation; Whole-Body Irradiation

1988
High dose busulfan/etoposide as a preparatory regimen for second bone marrow transplants in hematologic malignancies.
    Blut, 1987, Volume: 55, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Etoposide; Follow-Up Studies; Humans; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Whole-Body Irradiation

1987
[Postoperative therapy of epithelial ovarian cancer at the Göttingen University Gynecologic Clinic. A retrospective analysis of 82 patients 1981-1984].
    Geburtshilfe und Frauenheilkunde, 1986, Volume: 46, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Reoperation

1986
Drug-induced histological changes in rat seminiferous tubular epithelium.
    Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement, 1980, Volume: 4

    Topics: Animals; Antispermatogenic Agents; Busulfan; Cadmium; Epithelial Cells; Estradiol; Etoposide; Indenes; Male; Pyridines; Rats; Seminiferous Tubules; Testis

1980
[Autologous bone marrow transplantation following high-dose busulfan and etoposide for a patient with non-Hodgkin's lymphoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lymphoma, Large-Cell, Immunoblastic; Male; Transplantation, Autologous

1994
Severe esophageal stricture after autologous bone marrow transplant.
    Bone marrow transplantation, 1995, Volume: 15, Issue:6

    Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Esophageal Stenosis; Esophagitis; Etoposide; Fatal Outcome; Female; Humans; Immunocompromised Host; Leukemia, Myeloid; Melphalan; Middle Aged

1995
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
    Bone marrow transplantation, 1995, Volume: 15, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukapheresis; Lymphocyte Count; Lymphocyte Subsets; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Mesna; Middle Aged; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors; Treatment Outcome; Vincristine

1995
Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation.
    Bone marrow transplantation, 1995, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia; Lung; Lymphoma; Male; Middle Aged; Recurrence; Skin; Survival Rate; Transplantation, Autologous; Transplantation, Homologous

1995
Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Platelet Transfusion; Recurrence; Remission Induction; Survival Analysis; Thiotepa; Transplantation, Homologous; Whole-Body Irradiation

1995
Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation.
    Blood, 1995, Jun-01, Volume: 85, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Busulfan; Carmustine; Cell Count; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasms; Prognosis; Radiation Injuries; Treatment Outcome; Vincristine; Whole-Body Irradiation

1995
[Excretion of beta-2-microglobulin and Tamm-Horsfall protein in patients undergoing a conditioning regimen before bone marrow transplantation].
    Polskie Archiwum Medycyny Wewnetrznej, 1994, Volume: 92, Issue:5

    Topics: Adjuvants, Immunologic; Adult; beta 2-Microglobulin; Bone Marrow Transplantation; Busulfan; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Tubules; Male; Mucoproteins; Preoperative Care; Uromodulin

1994
Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis.
    Bone marrow transplantation, 1994, Volume: 13, Issue:4

    Topics: Acute Disease; Adolescent; Adult; Blood Component Transfusion; Busulfan; Combined Modality Therapy; Etoposide; Female; Flow Cytometry; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Myeloid; Leukocyte Count; Leukopenia; Lymphocyte Subsets; Lymphoma; Male; Middle Aged; Nitrosourea Compounds; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma

1994
Allogeneic bone marrow transplantation following busulfan-cyclophosphamide with or without etoposide conditioning regimen for patients with acute lymphoblastic leukaemia.
    British journal of haematology, 1993, Volume: 85, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Humans; Infant; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Recurrence; Transplantation, Homologous

1993
Busulfan-containing pre-transplant regimens for the treatment of solid tumors.
    Bone marrow transplantation, 1994, Volume: 14, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasms; Ovarian Neoplasms; Pilot Projects; Retrospective Studies; Sarcoma

1994
Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Chromatography, High Pressure Liquid; Drug Interactions; Etoposide; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Phenytoin; Therapeutic Equivalency

1994
Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children.
    International journal of radiation oncology, biology, physics, 1994, Apr-30, Volume: 29, Issue:1

    Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infant; Leukemia; Lung Diseases, Interstitial; Lymphoma; Male; Middle Aged; Retrospective Studies; Skin Diseases; Whole-Body Irradiation

1994
Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients.
    Bone marrow transplantation, 1993, Volume: 12, Issue:4

    Topics: Adolescent; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Child; Cyclophosphamide; Etoposide; Gastrointestinal Diseases; Hepatic Veno-Occlusive Disease; Humans; Hyperbilirubinemia; Incidence; Infusions, Intravenous; Kidney Diseases; Middle Aged; Pentoxifylline; Survival Analysis; Treatment Outcome; Tumor Necrosis Factor-alpha; Whole-Body Irradiation

1993
Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.
    Seminars in oncology, 1993, Volume: 20, Issue:4 Suppl 4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Middle Aged; Premedication; Remission Induction; Survival Analysis; Transplantation, Autologous; Treatment Outcome

1993
Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies.
    Seminars in oncology, 1993, Volume: 20, Issue:4 Suppl 4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Humans; Lymphoma; Middle Aged; Survival Analysis; Treatment Outcome

1993
Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen.
    Blood, 1993, Jan-15, Volume: 81, Issue:2

    Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid; Recurrence; Survival Analysis; Time Factors; Transplantation, Autologous

1993
Role of total body irradiation as based on the comparison of preparation regimens for allogeneic bone marrow transplantation for acute leukemia in first complete remission.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1993, Volume: 169, Issue:4

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Humans; Infant; Japan; Leukemia; Male; Methotrexate; Nimustine; Proportional Hazards Models; Radiotherapy Dosage; Remission Induction; Transplantation, Homologous; Whole-Body Irradiation

1993
Antitumor activity of treosulfan in human lung carcinomas.
    Cancer chemotherapy and pharmacology, 1996, Volume: 37, Issue:3

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Male; Mice; Mice, Nude; Mitomycin; Neoplasm Transplantation; Time Factors

1996
Association of busulfan area under the curve with veno-occlusive disease following BMT.
    Bone marrow transplantation, 1996, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Busulfan; Circadian Rhythm; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Hepatic Veno-Occlusive Disease; Humans; Male; Middle Aged; Retrospective Studies; Risk

1996
Late relapse after autologous BMT.
    Leukemia, 1996, Volume: 10, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Time Factors

1996
Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
    Bone marrow transplantation, 1996, Volume: 18, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Life Tables; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thioguanine; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation

1996
Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced leukemia.
    Bone marrow transplantation, 1996, Volume: 18, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Leukemia; Treatment Outcome

1996
The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:1

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Evaluation Studies as Topic; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute

1996
[High-dose chemotherapy with autologous stem cell rescue in patients with recurrent and high-risk pediatric brain tumors].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1997, Volume: 173, Issue:10

    Topics: Age Factors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Carboplatin; Child; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Risk Factors; Time Factors

1997
Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.
    Bone marrow transplantation, 1997, Volume: 20, Issue:10

    Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Life Tables; Male; Multiple Organ Failure; Neoplasms; Severity of Illness Index; Survival Analysis; Thrombophilia; Transplantation Conditioning; Treatment Outcome

1997
Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha.
    British journal of haematology, 1998, Volume: 101, Issue:1

    Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Lenograstim; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Recombinant Proteins; Treatment Outcome

1998
Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.
    Bone marrow transplantation, 1998, Volume: 21, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged

1998
Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report.
    Bone marrow transplantation, 1998, Volume: 22, Issue:9

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Etoposide; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Middle Aged; Transplantation, Autologous

1998
High-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in children with high-risk NHL and ALL-preliminary results.
    Bone marrow transplantation, 1998, Volume: 22 Suppl 4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclosporine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation, Autologous; Treatment Outcome

1998
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Bone marrow transplantation, 1999, Volume: 23, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine

1999
[Severe esophageal stenosis secondary to the administration of chemotherapy in a patient with acute myeloblastic leukemia].
    Sangre, 1999, Volume: 44, Issue:3

    Topics: Anti-Infective Agents; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dilatation; Esophageal Stenosis; Esophagitis; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Recurrence; Remission Induction; Transplantation Conditioning; Ulcer

1999
Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation.
    Free radical biology & medicine, 2000, Mar-15, Volume: 28, Issue:6

    Topics: Allantoin; Antineoplastic Agents; Antioxidants; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Fatty Acids, Unsaturated; Hematologic Neoplasms; Humans; Iron; Lipid Peroxides; Oxidative Stress; Reactive Oxygen Species; Statistics, Nonparametric; Ubiquinone; Uric Acid; Whole-Body Irradiation

2000
Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Bone marrow transplantation, 2000, Volume: 26, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid; Leukocytes; Male; Middle Aged; Recurrence; Survival Rate; Transplantation Conditioning; Treatment Outcome

2000
High-dose chemotherapy with autologous stem cell support in an adult with bone marrow relapse of medulloblastoma.
    Bone marrow transplantation, 2000, Volume: 26, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Busulfan; Carboplatin; Cerebellar Neoplasms; Combined Modality Therapy; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Male; Medulloblastoma; Radiotherapy, Adjuvant; Remission Induction; Salvage Therapy; Thiotepa; Transplantation, Autologous

2000
High-dose chemotherapy and autologous stem cell rescue for acute myeloid leukemia remains a safe, effective, and valid option.
    Transplantation proceedings, 2000, Volume: 32, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Melphalan; Middle Aged; Platelet Count; Recombinant Proteins; Reproducibility of Results; Safety; Survival Rate; Transplantation, Autologous

2000
A pilot study of busulfan, cyclophosphamide and etoposide followed by autologous transplantation for acute myeloid leukemia in remission.
    Acta haematologica, 2000, Volume: 104, Issue:2-3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Recurrence; Remission Induction; Transplantation, Autologous

2000
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
    International journal of radiation oncology, biology, physics, 2001, Mar-15, Volume: 49, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation

2001
Systemic fusariosis after a preparative regimen including thiotepa, VP-16 and busulfan used for blood stem cell transplantation in Hodgkin's disease.
    Leukemia & lymphoma, 2001, Volume: 40, Issue:3-4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Etoposide; Fatal Outcome; Fusarium; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Mycoses; Thiotepa; Transplantation Conditioning

2001
Autologous peripheral blood progenitor cell transplantation for transformed diffuse large-cell lymphoma.
    Clinical lymphoma, 2000, Volume: 1, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Transformation, Neoplastic; Cyclophosphamide; Disease-Free Survival; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Retrospective Studies; Survival Rate; Transplantation, Autologous; Treatment Outcome

2000
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
    Blood, 2002, Jan-01, Volume: 99, Issue:1

    Topics: Amsacrine; Anthracyclines; Antineoplastic Agents; Busulfan; Cell Survival; Child; Child, Preschool; Cytarabine; Down Syndrome; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Thioguanine; Vincristine

2002
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bone marrow transplantation, 2001, Volume: 28, Issue:8

    Topics: Adolescent; Alkylating Agents; Area Under Curve; Bayes Theorem; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Genetic Diseases, Inborn; Graft Survival; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Humans; Incidence; Infant; Life Tables; Male; Melphalan; Prospective Studies; Severe Combined Immunodeficiency; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2001
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Haematologica, 2002, Volume: 87, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Infant; Leukemia; Life Tables; Male; Methylprednisolone; Middle Aged; Premedication; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation

2002
Autologous stem cell transplantation for advanced acute myeloid leukemia.
    Bone marrow transplantation, 2002, Volume: 29, Issue:4

    Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Count; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Cytogenetics; Disease-Free Survival; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Translocation, Genetic; Transplantation, Autologous

2002
Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Annals of hematology, 2002, Volume: 81, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Autologous

2002
Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation.
    Bone marrow transplantation, 2002, Volume: 29, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Chronic Disease; Combined Modality Therapy; Cyclophosphamide; Epstein-Barr Virus Infections; Etoposide; Female; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; In Situ Hybridization; Lymphoma; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous

2002
Allogeneic BMT for infantile acute leukemia: what is the optimal conditioning regimen?
    Bone marrow transplantation, 2002, Volume: 29, Issue:7

    Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Etoposide; Growth Disorders; Humans; Infant; Leukemia; Radiation Injuries; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Whole-Body Irradiation

2002
[Results of treatment of children with chronic myelogenous leukaemia (CML) obtained by the Polish Paediatric Leukaemia/Lymphoma Study Group].
    Medycyna wieku rozwojowego, 2000, Volume: 4, Issue:1 Suppl 2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Hydroxyurea; Infant; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mercaptopurine; Poland; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome

2000
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
    Blood, 2002, Nov-01, Volume: 100, Issue:9

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.
    International journal of oncology, 2003, Volume: 22, Issue:5

    Topics: Animals; Antineoplastic Agents; BRCA1 Protein; Busulfan; Camptothecin; Cell Division; Cell Line; Doxorubicin; Etoposide; Fibroblasts; Gene Deletion; Genes, BRCA1; Mice; Mitoxantrone; Topotecan; Tumor Suppressor Protein p53

2003
Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma.
    American journal of hematology, 2003, Volume: 73, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Immunosuppression Therapy; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Platelet Count; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation, Autologous; Whole-Body Irradiation

2003
Esophageal actinomycosis after allogeneic peripheral blood stem cell transplantation for extranodal natural killer/T cell lymphoma, nasal type.
    Bone marrow transplantation, 2003, Volume: 32, Issue:4

    Topics: Actinomycosis; Adult; Busulfan; Cyclophosphamide; Esophageal Diseases; Etoposide; Humans; Immunosuppressive Agents; Killer Cells, Natural; Lymphoma, T-Cell; Male; Peripheral Blood Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous

2003
Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
    Haematologica, 2004, Volume: 89, Issue:1

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous

2004
[Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma].
    Bulletin du cancer, 2004, Volume: 91, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Eye Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, T-Cell; Middle Aged; Prognosis; Recurrence; Thiotepa

2004
Nephrotic syndrome in patients with peripheral blood stem cell transplant.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:4

    Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytomegalovirus Infections; Etoposide; Glomerulonephritis, Membranous; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Prednisone; Rituximab; Sepsis; Staphylococcal Infections; Tacrolimus; Transplantation Conditioning

2005
Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin.
    Stem cells and development, 2005, Volume: 14, Issue:2

    Topics: Adult; Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cell Culture Techniques; Cell Proliferation; Cell Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Lewis X Antigen; Lipopolysaccharide Receptors; Lymphoma; Male; Microscopy, Fluorescence; Middle Aged; Myelodysplastic Syndromes; Nucleic Acid Synthesis Inhibitors; Stromal Cells; Transplantation Conditioning; Vidarabine

2005
The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen.
    Pediatric blood & cancer, 2006, Volume: 47, Issue:7

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2006
High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Busulfan; Combined Modality Therapy; Disease Progression; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Neoplasm Recurrence, Local; Sarcoma, Ewing; Treatment Outcome

2006
Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:7

    Topics: Administration, Oral; Adolescent; Adult; Aged; Busulfan; Chi-Square Distribution; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Secondary Prevention; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous

2006
High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.
    Leukemia research, 2007, Volume: 31, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation, Autologous

2007
Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:12

    Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Registries; Remission Induction; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; United Kingdom; Whole-Body Irradiation

2006
Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Lung Diseases; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Tumor Burden

2006
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
    Haematologica, 2007, Volume: 92, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2007
Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen.
    Bone marrow transplantation, 2007, Volume: 40, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Autologous

2007
Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation--a similar experience.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Drug Evaluation; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Longitudinal Studies; Male; Middle Aged; Transplantation, Autologous; Treatment Outcome

2007
Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma.
    Bone marrow transplantation, 2007, Volume: 40, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Transplantation Conditioning; Treatment Outcome

2007
Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma.
    International journal of hematology, 2007, Volume: 86, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Infant; Leukemia; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Nimustine; Recurrence; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous

2007
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-01, Volume: 26, Issue:28

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Busulfan; Cytarabine; Daunorubicin; Etoposide; Female; fms-Like Tyrosine Kinase 3; Genes, Wilms Tumor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nucleophosmin; Prognosis; Proportional Hazards Models; Statistics, Nonparametric

2008
Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.
    Bone marrow transplantation, 2008, Volume: 42, Issue:7

    Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Busulfan; Carboplatin; Child; Child, Preschool; Clonazepam; Etoposide; Female; Hepatic Veno-Occlusive Disease; Humans; Infant; Male; Retrospective Studies; Risk Factors; Sarcoma; Seizures; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2008
Mucoepidermoid carcinoma of the submandibular gland after chemotherapy in a child.
    Auris, nasus, larynx, 2009, Volume: 36, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Busulfan; Carcinoma, Mucoepidermoid; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Image Processing, Computer-Assisted; Leukemia, Myeloid, Acute; Male; Neck Dissection; Neoplasms, Second Primary; Positron-Emission Tomography; Submandibular Gland Neoplasms; Thioguanine; Tomography, X-Ray Computed; Transplantation Conditioning

2009
[Autologous hematopoietic stem cell transplantation followed by oral bexarotene in a patient with advanced mycosis fungoides].
    Actas dermo-sifiliograficas, 2008, Volume: 99, Issue:7

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Busulfan; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Interferon alpha-2; Interferon-alpha; Mechlorethamine; Methylprednisolone; Mycosis Fungoides; Peripheral Blood Stem Cell Transplantation; Prednisone; PUVA Therapy; Recombinant Proteins; Remission Induction; Tetrahydronaphthalenes; Transplantation, Autologous; Vincristine

2008
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Drug Evaluation; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation, Autologous

2008
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
    Acta pharmacologica Sinica, 2009, Volume: 30, Issue:10

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Idarubicin; Immunosuppressive Agents; Leukemia; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Mucositis; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Retrospective Studies; Risk Factors; Semustine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation

2009
Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide.
    British journal of haematology, 2010, Volume: 148, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Busulfan; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2010
Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY.
    Bone marrow transplantation, 2011, Volume: 46, Issue:2

    Topics: Adult; Busulfan; Cyclophosphamide; Cytomegalovirus; Etoposide; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Transplantation Conditioning; Treatment Outcome; Virus Activation

2011
Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?
    International journal of radiation oncology, biology, physics, 2011, Sep-01, Volume: 81, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Case-Control Studies; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Etoposide; Female; Hodgkin Disease; Humans; Male; Middle Aged; Radiotherapy; Secondary Prevention; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Tumor Burden; Young Adult

2011
Intramedullary PNET of the spine: long-term survival after combined modality therapy and subsequent relapse.
    Journal of pediatric hematology/oncology, 2011, Volume: 33, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cerebellar Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Female; Humans; Methylprednisolone Hemisuccinate; Neuroectodermal Tumors, Primitive; Neuroprotective Agents; Radiotherapy; Spinal Neoplasms; Temozolomide; Thiotepa; Thoracic Vertebrae; Vincristine; Young Adult

2011
Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases.
    The American Journal of dermatopathology, 2011, Volume: 33, Issue:4

    Topics: Alopecia; Antineoplastic Agents; Busulfan; Cisplatin; Dermis; Diagnosis, Differential; Docetaxel; Etoposide; Female; Hair; Humans; Male; Neoplasms; Taxoids

2011
Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
    Journal of neuro-oncology, 2011, Volume: 105, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Rituximab; Salvage Therapy; Thiotepa; Young Adult

2011
In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells.
    Leukemia research, 2011, Volume: 35, Issue:11

    Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Busulfan; Cell Line, Tumor; Daunorubicin; Drug Interactions; Drug Synergism; Etoposide; Exotoxins; Flow Cytometry; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia; Leukocytes; Lymphocyte Function-Associated Antigen-1; Membrane Potential, Mitochondrial; Mitoxantrone; Piperazines; Pyrimidines; Tumor Cells, Cultured

2011
Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Disease Progression; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Radiotherapy; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult

2011
Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Child; Child, Preschool; Computer Simulation; Cyclophosphamide; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Etoposide; Female; Humans; Infant; Male; Melphalan; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neoplasms; Protein Binding

2012
Outcome of allogeneic stem cell transplantation with a conditioning regimen of busulfan, cyclophosphamide and low-dose etoposide for children with myelodysplastic syndrome.
    Hematology/oncology and stem cell therapy, 2011, Volume: 4, Issue:3

    Topics: Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Immunosuppressive Agents; Infant; Kaplan-Meier Estimate; Male; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2011
Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.
    Journal of pediatric surgery, 2011, Volume: 46, Issue:11

    Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Busulfan; Carboplatin; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Male; Melphalan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Vidarabine; Vincristine

2011
Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Cyclophosphamide; Drug Administration Routes; Etoposide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous

2012
Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Melphalan; Myeloablative Agonists; Neoplasm Metastasis; Prognosis; Sarcoma, Ewing; Stem Cell Transplantation; Vincristine; Young Adult

2012
Non-TBI hematopoietic stem cell transplantation in pediatric AML patients: a single-center experience.
    Journal of pediatric hematology/oncology, 2013, Volume: 35, Issue:6

    Topics: Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Myeloablative Agonists; Proportional Hazards Models; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous

2013
Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens.
    Annals of hematology, 2013, Volume: 92, Issue:5

    Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Biphenotypic, Acute; Male; Middle Aged; Retrospective Studies; Standard of Care; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation; Young Adult

2013
Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
    Annals of hematology, 2013, Volume: 92, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Induction Chemotherapy; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Mucositis; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult

2013
[Busulfan, cyclophosphamide and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:4

    Topics: Adult; Busulfan; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2013
Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia.
    Journal of human genetics, 2013, Volume: 58, Issue:6

    Topics: Adolescent; Adult; Aged; Busulfan; Chromosome Mapping; Cytarabine; Disease-Free Survival; DNA; Etoposide; Female; Follow-Up Studies; Genetic Loci; Genotype; Glutathione Transferase; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Membrane Transport Proteins; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Proportional Hazards Models; Remission Induction; Young Adult

2013
Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission.
    International journal of hematology, 2013, Volume: 98, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Autografts; Busulfan; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Survival Rate; Transplantation Conditioning

2013
Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult

2014
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Registries; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation

2015
Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers.
    Pediatric transplantation, 2016, Volume: 20, Issue:2

    Topics: Adolescent; Antineoplastic Agents; Boston; Brain Neoplasms; Busulfan; Carboplatin; Child; Child, Preschool; Egypt; Etoposide; Humans; Infant; Infant, Newborn; Melphalan; Neuroblastoma; Retrospective Studies; Transplantation Conditioning; Treatment Outcome

2016
Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Carboplatin; Child; Child, Preschool; Critical Care; Databases, Factual; Etoposide; Female; Follow-Up Studies; Humans; Incidence; Infant; Length of Stay; Male; Melphalan; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Sepsis; Stem Cells; Transplantation Conditioning; United States

2016
Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
    Bone marrow transplantation, 2016, Volume: 51, Issue:9

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Child; Child, Preschool; Cohort Studies; Etoposide; Female; Hepatic Veno-Occlusive Disease; Humans; Hypertension, Pulmonary; Infant; Kidney Diseases; Male; Melphalan; Mucositis; Myeloablative Agonists; Neuroblastoma; Pancytopenia; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Young Adult

2016
Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:9

    Topics: Adult; Aged; Busulfan; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Liver Function Tests; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Respiratory Function Tests; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; Young Adult

2016
Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 91

    Topics: Adolescent; Age Factors; Antineoplastic Agents; Area Under Curve; Busulfan; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Drug Dosage Calculations; Drug Monitoring; Etoposide; Humans; Infant; Models, Biological; Neoplasms; Patient Safety; Risk Factors

2018
Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.
    Pediatric blood & cancer, 2018, Volume: 65, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Carboplatin; Child; Child, Preschool; Databases, Factual; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Length of Stay; Male; Melphalan; Neuroblastoma; Stem Cell Transplantation

2018
Acute Complications After High-Dose Chemotherapy and Stem-Cell Rescue in Pediatric Patients With High-Risk Neuroblastoma Treated in Countries With Different Resources.
    Journal of global oncology, 2018, Volume: 4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Carboplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Egypt; Etoposide; Female; Humans; Male; Melphalan; Middle Aged; Neuroblastoma; Stem Cell Transplantation; Transplantation Conditioning

2018
Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation.
    Annals of hematology, 2019, Volume: 98, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Semustine; Survival Rate; Transplantation Conditioning

2019
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Young Adult

2019
Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.
    Annals of hematology, 2019, Volume: 98, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System Neoplasms; Consolidation Chemotherapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphoma; Male; Middle Aged; Prospective Studies; Registries; Stem Cell Transplantation; Survival Rate; Thiotepa

2019
Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL).
    Bone marrow transplantation, 2020, Volume: 55, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Melphalan; Transplantation Conditioning; Transplantation, Autologous

2020
Tandem high-dose chemotherapy with autologous stem cell rescue for stage M high-risk neuroblastoma: Experience using melphalan/etoposide/carboplatin and busulfan/melphalan regimens.
    Pediatric transplantation, 2020, Volume: 24, Issue:7

    Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Child; Child, Preschool; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Neoplasm Staging; Neuroblastoma; Retrospective Studies; Transplantation, Autologous

2020
Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL.
    Journal of pediatric hematology/oncology, 2021, Oct-01, Volume: 43, Issue:7

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Organophosphorus Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2021
BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas.
    Leukemia research, 2021, Volume: 110

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2021
Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation with Cocktail Conditioning Regimen for the Treatment of Pediatric Patients with Chronic Active Epstein-Barr Virus: A Retrospective Observational Study.
    Stem cells and development, 2022, Volume: 31, Issue:1-2

    Topics: Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Epstein-Barr Virus Infections; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; Humans; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous

2022
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
    Bone marrow transplantation, 2022, Volume: 57, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Central Nervous System; Central Nervous System Neoplasms; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Neoplasm Recurrence, Local; Prospective Studies; Thiotepa; Transplantation, Autologous; Treatment Outcome

2022
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
    Journal of pharmaceutical and biomedical analysis, 2022, Nov-30, Volume: 221

    Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water

2022
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial.
    Leukemia, 2022, Volume: 36, Issue:11

    Topics: Busulfan; Child; Cyclophosphamide; Etoposide; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Neoplasms; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation

2022
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party
    Bone marrow transplantation, 2023, Volume: 58, Issue:11

    Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous

2023
chemdatabank.com